Radar Telegram alerts Open Radar

PMV Pharmaceuticals announces promising updated data from the PYNNACLE Phase 2 pivotal trial of Rezatapopt monotherapy in patients with advanced solid tumors harboring the TP53 Y220C mutation.

תרגם לעברית

Business Insider Markets · · Source

PMV Pharmaceuticals announces promising updated data from the PYNNACLE Phase 2 pivotal trial of Rezatapopt monotherapy in patients with advanced solid tumors harboring the TP53 Y220C mutation.

More on Radar

Want to see every report in real time?

Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.

Sign up free
Share on WhatsApp Get alerts on Telegram